{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:16:13Z","timestamp":1780557373616,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008721","name":"University College London Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.rpth.2024.102327","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T12:04:25Z","timestamp":1706270665000},"page":"102327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrual"],"prefix":"10.1016","volume":"8","author":[{"given":"Pedro","family":"Gaspar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabal","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102327_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102327_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2024.102327_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/clpt.2013.99","article-title":"Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis","volume":"94","author":"Lopes","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rpth.2024.102327_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2024.102327_bib5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/0961203314534308","article-title":"Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality","volume":"23","author":"Dall\u2019Ara","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102327_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/0961203320933009","article-title":"Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center","volume":"29","author":"Serrano","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102327_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the systemic lupus international collaborating clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rpth.2024.102327_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rpth.2024.102327_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0961203320901598","article-title":"Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus","volume":"29","author":"Torricelli","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102327_bib10","first-page":"605","article-title":"A\u00a0one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome","volume":"41","author":"Gaspar","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rpth.2024.102327_bib11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0961203315576858","article-title":"Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)","volume":"24","author":"Amigo","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102327_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/rheumatology\/keaa172","article-title":"The assessment of patients with the antiphospholipid antibody syndrome: where are we now?","volume":"59","author":"Gaspar","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rpth.2024.102327_bib13","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102327_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102327_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102327_bib16","first-page":"474","article-title":"Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation","volume":"16","author":"Balc\u0131","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.rpth.2024.102327_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hjc.2018.06.012","article-title":"Health-related quality of life after adverse bleeding events associated with antithrombotic drug therapy \u2013 a systematic review","volume":"60","author":"Res","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.rpth.2024.102327_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/europace\/eut001","article-title":"Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies","volume":"15","author":"Roskell","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.rpth.2024.102327_bib19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102327_bib20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00228-020-02856-6","article-title":"Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication","volume":"76","author":"Rydberg","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2024.102327_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1378\/chest.07-2627","article-title":"Outcomes associated with combined antiplatelet and anticoagulant therapy","volume":"133","author":"Johnson","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2024.102327_bib22","first-page":"CD012169","article-title":"Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome","author":"Bala","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2024.102327_bib23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archinte.162.10.1164","article-title":"Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5","volume":"162","author":"Ruiz-Irastorza","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rpth.2024.102327_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejim.2021.07.004","article-title":"Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS)","volume":"92","author":"Radin","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rpth.2024.102327_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/0961203320970651","article-title":"Damage index for antiphospholipid syndrome during long term follow-up: correlation between organ damage accrual and quality of life","volume":"30","author":"Medina","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102327_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/dj4010005","article-title":"New direct oral anticoagulants (DOAC) and their use today","volume":"4","author":"Schwarb","year":"2016","journal-title":"Dent J (Basel)"},{"key":"10.1016\/j.rpth.2024.102327_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102711","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"20","author":"Dufrost","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rpth.2024.102327_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102327_bib29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.autrev.2017.09.004","article-title":"Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?","volume":"16","author":"Sciascia","year":"2017","journal-title":"Autoimmun Rev"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:31:06Z","timestamp":1762864266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2475037924000141"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102327","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrual","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102327"}}